• Pharmascience Launches (Pr)pms-TRANDOLAPRIL americanpharmaceuticalreview
    July 11, 2018
    Pharmascience has launched in Canada Prpms-TRANDOLAPRIL (angiotensin-converting enzyme inhibitor), indicated for the treatment of mild to moderate essential hypertension and the treatment following acute myocardial infarction.
PharmaSources Customer Service